Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6474)
All Articles published online
|
Publishing Process of This Article
|
Jul 15, 2022 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264 [PMID: 36051096 DOI: 10.4251/wjgo.v14.i7.1252] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v14/i7/1252.htm |
| Number | Citing Articles |
| 1 |
Tongxin Zhang, Zilong He, Yankui Liu, Linfang Jin, Teng Wang. High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer. International Journal of General Medicine 2024; : 1695 doi: 10.2147/IJGM.S453883
|
| 2 |
Hyein Jeon, Michelle Sterpi, Christiana Mo, Fernand Bteich. Claudins: from gatekeepers of epithelial integrity to potential targets in hepato-pancreato-biliary cancers. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1454882
|
| 3 |
Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W.M. De Groof, Nick Devoogdt. Current status and future expectations of nanobodies in oncology trials. Expert Opinion on Investigational Drugs 2023; 32(8): 705 doi: 10.1080/13543784.2023.2249814
|
| 4 |
Chiara Deiana, Margherita Agostini, Giovanni Brandi, Elisa Giovannetti. The trend toward more target therapy in pancreatic ductal adenocarcinoma. Expert Review of Anticancer Therapy 2024; 24(7): 525 doi: 10.1080/14737140.2024.2357802
|
| 5 |
Gyerim Park, Se Jun Park, Younghoon Kim. Clinicopathological significance and prognostic values of claudin18.2 expression in solid tumors: a systematic review and meta-analysis. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1453906
|
| 6 |
Jinxia Chen, Zhiyuan Xu, Can Hu, Shengjie Zhang, Mengli Zi, Li Yuan, Xiangdong Cheng. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1132319
|
| 7 |
Andrew Hall, Sarah R. Brown, Niharika B. Mettu, Paul C. Miller, Elizabeth C. Smyth, Andrew B. Nixon. Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies. American Society of Clinical Oncology Educational Book 2024; 44(3) doi: 10.1200/EDBK_433640
|
| 8 |
Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen, Kohei Shitara. Claudin 18.2 as a novel therapeutic target. Nature Reviews Clinical Oncology 2024; 21(5): 354 doi: 10.1038/s41571-024-00874-2
|
| 9 |
|
| 10 |
Fangqian Du, Yuwei Xie, Shengze Wu, Mengling Ji, Bingzi Dong, Chengzhan Zhu. Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases. Journal of Hepatocellular Carcinoma 2024; : 1801 doi: 10.2147/JHC.S483861
|
| 11 |
Guocheng Zhong, Xiaomin Zhang, Zheng Guo, Yujie Gao, Bochen Zhao, Xianhao Liu, Lei Chen, Jingqiao Qiao, Chuan Yu, Lixin Wang, Yisheng Li, Li Yu. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1325860
|
| 12 |
Caroline Hana, Nyein Nyein Thaw Dar, Michael Galo Venegas, Michel Vulfovich. Claudins in Cancer: A Current and Future Therapeutic Target. International Journal of Molecular Sciences 2024; 25(9): 4634 doi: 10.3390/ijms25094634
|
| 13 |
Yuming Wang, Yike Gao, Zhiwen Zhang, Zixin Zhang, Anqi Wang, Kun Zhao, Miao Zhang, Sumei Zhang, Mei Li, Jian Sun, Dan Guo, Zhiyong Liang. Claudin18.2 expression in pulmonary mucinous adenocarcinoma. Journal of Cancer Research and Clinical Oncology 2023; 149(14): 12923 doi: 10.1007/s00432-023-05150-x
|
| 14 |
Pankti C. Balar, Vasso Apostolopoulos, Vivek P. Chavda. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way. European Journal of Pharmacology 2024; 969: 176451 doi: 10.1016/j.ejphar.2024.176451
|
| 15 |
Manon Brunet, Claire Vargas, Marjorie Fanjul, Damien Varry, Naïma Hanoun, Dorian Larrieu, Laetitia Pieruccioni, Guillaume Labrousse, Hubert Lulka, Florence Capilla, Alban Ricard, Janick Selves, Anne Couvelard, Véronique Gigoux, Pierre Cordelier, Julie Guillermet‐Guibert, Marlène Dufresne, Jérôme Torrisani. The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and pancreatic carcinogenesis. The Journal of Pathology 2024; 263(4-5): 466 doi: 10.1002/path.6298
|
| 16 |
Annalisa Schirizzi, Aram Arshadi, Doron Tolomeo, Laura Schirosi, Anna Maria Valentini, Giampiero De Leonardis, Maria Grazia Refolo, Rossella Donghia, Clelia Tiziana Storlazzi, Alfredo Zito, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Maria Bencivenga, Giovanni De Manzoni, Caterina Messa, Raffaele Armentano, Gianluigi Giannelli, Claudio Lotesoriere, Rosalba D’Alessandro. VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment. Biomedicines 2023; 11(10): 2721 doi: 10.3390/biomedicines11102721
|
| 17 |
Chen Wang, Na Wu, Beibei Pei, Xiaoyan Ma, Wenhui Yang. Claudin and pancreatic cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1136227
|
| 18 |
Marta Łukaszewicz-Zając, Barbara Mroczko. Claudins—Promising Biomarkers for Selected Gastrointestinal (GI) Malignancies?. Cancers 2023; 16(1): 152 doi: 10.3390/cancers16010152
|
| 19 |
Rachael A. Safyan, Eejung Kim, Emmelie Dekker, Marjolein Homs, Andrew J. Aguirre, Bas Groot Koerkamp, E. Gabriela Chiorean. Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer. American Society of Clinical Oncology Educational Book 2024; 44(3) doi: 10.1200/EDBK_438598
|
| 20 |
Su Ir Lyu, Caroline Fretter, Adrian Georg Simon, Sarah-Michele Spielmann, Alexander I. Damanakis, Yue Zhao, Christiane J. Bruns, Thomas Schmidt, Felix C. Popp, Dirk Waldschmidt, Alexander Quaas, Karl Knipper. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Translational Oncology 2024; 47: 102044 doi: 10.1016/j.tranon.2024.102044
|